Healthcare M&A News, Deals & Transaction Activity

Quoin Pharmaceuticals entered into a securities purchase agreement to raise up to approximately $50 million, including about $30.8 million of upfront funding and up to approximately $19.2 million from the potential exercise of accompanying warrants.

Capital signal: Late-clinical-stage specialty pharmaceutical companies can use private placements to extend development runway without a control transaction. Warrant-based structures can also create contingent follow-on capital beyond the initial funding at closing.

AusperBio closed a $120 million Series C financing to advance AHB-137 toward potential commercialization, including its Phase 3 registrational program, while supporting additional hepatitis B programs.

Capital signal: Late-stage biopharma capital is concentrating around programs approaching pivotal development and commercialization. These rounds can fund both clinical execution and the infrastructure required to prepare for launch.

Metriport raised $26 million in new funding led by Matrix, with participation from ARTIS and Y Combinator, to expand its open-source healthcare data infrastructure platform and point-of-care clinical intelligence capabilities.

Capital signal: Capital is continuing to move toward healthcare data infrastructure that can normalize fragmented records and support clinical workflows, analytics and AI applications across provider organizations.

Savista acquired ABW Medical, an ambulatory revenue cycle management company serving federally qualified health centers, medical groups, rural health providers, managed service organizations and virtual-care organizations.

Transaction signal: Revenue-cycle consolidation is extending deeper into ambulatory and non-acute settings. Specialized workflow expertise, customer relationships and embedded EHR ecosystem access can create strategic value for scaled healthcare operations platforms.

Imagenet acquired Analytica Consulting, combining Imagenet’s healthcare payer operations capabilities with Analytica’s data engineering, analytics, artificial intelligence, data science, visualization and data-governance expertise.

Transaction signal: Healthcare operations platforms are acquiring data and AI capabilities to move beyond outsourced execution toward technology-enabled decision support. Domain expertise paired with proprietary analytics can broaden strategic relevance to payer customers.

argenx completed its acquisition of Forte Biosciences at $77 per share, adding Forte’s anti-CD122 antibody FB102 to its immunology pipeline. The transaction had an approximately $2.2 billion equity value when announced in July.

Transaction signal: Biopharma buyers continue to use acquisitions to secure differentiated clinical assets and broaden therapeutic pipelines. Completion of a large cash transaction also demonstrates strategic willingness to deploy balance-sheet capital around clinically validated mechanisms.

Sword Health plans to acquire Headspace’s parent company, OrangeDot, in an all-cash transaction. A regulatory filing did not disclose the purchase price, while media reports placed the value between approximately $200 million and $300 million.

Transaction signal: The proposed combination reflects continued consolidation across virtual care and digital behavioral health. Buyers are seeking broader clinical platforms, distribution and longitudinal member relationships rather than narrowly defined point solutions.

Globus Medical acquired Higgs Boson Health, a Duke-incubated digital healthcare experience company focused on AI-driven software for patients and providers across the episode of care.

Transaction signal: The acquisition shows a scaled medical-device company extending beyond hardware into digital workflow, patient engagement, and surgical intelligence. Strategic buyers may increasingly value software and AI capabilities that strengthen an installed clinical ecosystem.

Arintra raised a $25 million Series B led by Define Ventures to expand its AI-powered revenue-assurance platform for health systems and healthcare providers.

Capital signal: Revenue-cycle and revenue-assurance platforms continue to attract growth capital where AI can be tied to reimbursement accuracy, coding automation, denial prevention, and measurable financial outcomes for providers.

McKesson signed a definitive agreement to acquire Precision Medicine Group, a provider of clinical research and biopharma commercialization services, for approximately $2.25 billion.

Transaction signal: The transaction reflects strategic demand for outsourced clinical-development and commercialization capabilities that deepen relationships with biopharma customers and expand higher-growth service offerings around oncology and specialty care.

Radiology Partners entered into a definitive agreement to acquire Everlight Radiology from Livingbridge, adding an international teleradiology network serving hospitals, health systems, and imaging centers across multiple markets.

Transaction signal: The deal highlights the value of radiologist capacity, geographic coverage, 24/7 subspecialty availability, and technology-enabled workflow in a market where provider shortages can make scaled teleradiology infrastructure strategically important.

Gravity 360, the parent company of Gravity Diagnostics, acquired Med-Lake Laboratory, a full-service clinical laboratory serving providers and care organizations across Georgia, Alabama, and neighboring states.

Transaction signal: Regional laboratory consolidation can add test volume, provider relationships, payer connectivity, and geographic density. Buyers may also value accredited infrastructure and the ability to spread laboratory technology and operating systems across a wider footprint.

Switchboard Health acquired Livara Health, a virtual orthopedics and musculoskeletal care platform, and said it also closed more than $5 million of equity financing to support integration and growth.

Transaction signal: The combination shows specialty-care navigation platforms moving into direct care delivery. Integrating referral management with value-based MSK care can create a broader clinical and financial proposition for health plans, providers, and risk-bearing organizations.

Airway Therapeutics closed a $50 million equity round, including previously raised SAFE capital and a Series E-2 financing, to support late-stage development of zelpultide alfa.

Capital signal: Late-stage life-sciences financings continue to fund clinical execution, manufacturing readiness, and regulatory work around priority assets. Insider participation can extend runway through major development milestones without a control transaction.

VitalCaring acquired Carter Healthcare, expanding its home health and hospice presence in Ohio and West Virginia while strengthening operations across Oklahoma, Texas, Kansas, and Missouri.

Transaction signal: Home-based care buyers continue to use acquisitions to build branch density, expand referral networks, and broaden service coverage across home health and hospice. Clinical labor, reimbursement, census quality, and local operating scale remain central considerations.

Cityblock Health signed a definitive agreement to acquire Homeward Health in an all-stock transaction, combining urban and rural value-based care models serving Medicare, Medicaid, and dual-eligible populations.

Transaction signal: The transaction highlights consolidation among value-based care platforms seeking broader geography, larger covered populations, and stronger care-delivery infrastructure. Government-program scale and risk-bearing capabilities can be meaningful strategic assets.

Cityblock Health announced a $116 million Series E led by General Catalyst alongside its agreement to acquire Homeward Health.

Capital signal: The paired financing and acquisition illustrate how growth capital can directly support strategic expansion. Scaled provider platforms may use equity financing to strengthen liquidity, fund integration, and accelerate geographic or population growth.

Radial acquired Mindful Health Solutions, expanding a behavioral-health platform focused on interventional psychiatry and multispecialty mental-health services.

Transaction signal: The transaction points to continued consolidation in specialized behavioral health, where clinic networks, clinician expertise, neuromodulation capabilities, and emerging treatment modalities can support platform strategies.

MaxQ Medical closed a $31.5 million Series A to advance an all-in-one transurethral imaging and therapy platform for prostate care.

Capital signal: MedTech financings can fund clinical programs and product development around differentiated procedural technologies. Strategic investor participation can also provide validation as companies move toward clinical and commercial milestones.

Francisco Partners entered into a definitive agreement to acquire Weave Communications, an AI-powered patient-engagement and payments platform for healthcare practices, for approximately $650 million in equity value.

Transaction signal: The take-private underscores sponsor interest in vertical healthcare software with embedded communications, payments, and revenue-cycle workflows. Practice-level distribution and recurring software relationships can support strategic value beyond standalone point solutions.

R1 entered into an agreement to acquire Humata Health, adding AI-powered prior-authorization automation to its broader revenue-cycle operating platform.

Transaction signal: Healthcare IT buyers continue to acquire workflow-specific AI capabilities where the technology can reduce administrative friction and improve reimbursement. Prior authorization is a particularly strategic workflow because it sits between providers, payers, and patient access.

Hopscotch Primary Care raised $53 million in Series D financing to expand its technology-enabled, value-based primary-care model across rural communities.

Capital signal: Growth capital remains available for care-delivery models with measurable patient engagement, payer relationships, and a path to geographic expansion. Rural healthcare platforms can use financing to add clinics, clinicians, and technology-enabled operating capacity.

Fulcrum Therapeutics and Slate Medicines entered a definitive all-stock merger agreement that would create a company focused on Slate’s next-generation migraine therapeutics. The combined company is expected to operate as Slate Medicines and trade under the ticker SLTE.

Transaction signal: The transaction illustrates how public biotech companies can use strategic combinations to reset pipelines and capital structures around higher-conviction assets. It also underscores continued investor support for focused therapeutic platforms despite uneven financing conditions.

Veritas Capital-backed Gainwell Technologies secured a nearly $6 billion debt refinancing, including a new $2.64 billion loan and maturity extensions on existing second-lien term debt and senior secured notes.

Capital signal: Large healthcare technology platforms are using the credit markets to extend maturities and preserve strategic flexibility. Debt structure, lender protections, leverage and recurring customer relationships can matter as much as equity value in capital advisory work.

Affordable Care completed a recapitalization that reduced debt by approximately $1.0 billion, provided $75 million of new capital, extended maturities to 2031 and transferred ownership to existing lenders.

Capital signal: This is a direct example of healthcare capital advisory extending beyond equity raises: balance-sheet restructurings can combine debt reduction, new-money capital, maturity extensions and ownership changes to restore financial flexibility.

Thermo Fisher Scientific completed the sale of its microbiology business to Astorg for $1.1 billion. Astorg plans to operate the business as an independent microbiology diagnostics company serving clinical, pharmaceutical, and food-safety testing markets.

Transaction signal: The carve-out highlights sponsor appetite for scaled diagnostics platforms with recurring testing workflows, installed customer relationships, and stand-alone growth potential. It also reflects portfolio optimization by diversified healthcare and life-sciences companies.

InduPro raised a $77 million Series B to advance its lead bispecific antibody-drug conjugate through first-in-human development.

Capital signal: Biotech capital continues to concentrate around programs with defined clinical milestones and syndicates that include strategic pharmaceutical investors.

Infinimmune raised a $75 million Series A to move two antibody programs for eczema into clinical development.

Capital signal: Large Series A rounds remain available for differentiated therapeutic platforms with clear development plans and strategic investor participation.

CHG Healthcare acquired KREWE Anesthesia, a staffing company focused on certified registered nurse anesthetists and managed anesthesia services. KREWE’s founders are expected to remain with the business.

Transaction signal: Anesthesia staffing remains a constrained labor category. The transaction shows how scaled workforce platforms can use acquisitions to add hard-to-source clinical specialties and deepen managed-services capabilities.

Teledyne Technologies agreed to acquire Varex Imaging in a transaction valued at approximately $1.1 billion. Varex supplies X-ray imaging components and related technologies used across medical and industrial applications.

Transaction signal: The deal reinforces strategic interest in imaging components and enabling technologies that sit inside larger diagnostic and medical-device ecosystems. Buyers can value differentiated installed technologies, engineering depth, and broad OEM relationships.

iRhythm Technologies agreed to acquire VitalConnect for approximately $288 million, adding wearable cardiac monitoring technology and expanding its position in ambulatory heart monitoring.

Transaction signal: The transaction reflects continued strategic consolidation around connected cardiac diagnostics and remote monitoring. Device platforms are pairing hardware, data, and workflow capabilities to broaden longitudinal patient monitoring.

Kyndryl agreed to acquire Healthcare IT Leaders, a healthcare technology consulting firm serving health systems across applications, infrastructure, data, and digital modernization. The combination is intended to accelerate AI-led healthcare transformation services.

Transaction signal: Healthcare technology buyers are increasingly acquiring domain-specific services capabilities alongside software and infrastructure expertise. Clinical workflow knowledge and implementation talent can be as strategically important as the underlying technology.

Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront plus potential milestone payments that could bring total consideration to approximately $1.32 billion. The transaction expands Jazz’s rare-disease pipeline.

Transaction signal: Large biopharma buyers continue to use targeted acquisitions to replenish pipelines and acquire differentiated clinical assets. Milestone-heavy structures also show how consideration can be tied to development and regulatory outcomes.

LifeMine Therapeutics raised $188 million in Series E financing to advance clinical development of an immunosuppressant for transplant patients.

Capital signal: Late-stage private capital can recapitalize development plans around priority clinical assets and extend runway through major milestones.

Health Catalyst completed the sale of Vitalware, its revenue-integrity and chargemaster technology business, to Med-Metrix. The transaction sharpens Health Catalyst’s focus on its healthcare intelligence platform while adding revenue-cycle capabilities to Med-Metrix.

Transaction signal: Portfolio pruning and capability-focused acquisitions are both active in healthcare technology. Revenue-cycle platforms continue to attract interest where software and services can improve reimbursement accuracy and operating performance.

Expedition Therapeutics raised an oversubscribed $115 million Series B to advance its lead DPP1 inhibitor through phase 2 development and support pipeline expansion.

Capital signal: Series B rounds are funding clinical execution while also giving companies capital to pursue additional assets and business-development opportunities.

Wellinks closed a $10 million Series B to expand its cardiopulmonary remote-patient-monitoring and predictive-care platform.

Capital signal: Strategic health-system participation can validate device-plus-data models that integrate monitoring with care delivery.

KKR agreed to acquire medical-device contract manufacturer Integer Holdings in an all-cash transaction valued at approximately $5.7 billion. Integer provides outsourced development and manufacturing services across high-growth medical-device categories.

Transaction signal: The take-private underscores sponsor interest in scaled medtech manufacturing platforms with entrenched OEM relationships, regulated production capabilities, and exposure to long-duration device programs.

Ratio Therapeutics raised a $70 million Series C to advance its radiopharmaceutical oncology program and scale manufacturing capabilities.

Capital signal: Radiopharma financings increasingly pair clinical development with manufacturing investment, making capital planning central to execution.

SoundHealth closed an oversubscribed $12.25 million Series A to support commercialization and development of its FDA-cleared AI-powered wearable for rhinitis and sleep-related breathing disorders.

Capital signal: Early-stage device financings can accelerate commercialization when a product has regulatory clearance and a defined clinical use case.

CoreMap closed a $37 million Series C led by Medtronic to accelerate its next-generation electrophysiology mapping platform for atrial fibrillation.

Capital signal: Strategic investment by a major device company can provide both capital and commercial validation for specialized medical technology.

Epitel raised a $26 million Series B to expand its FDA-cleared wireless EEG monitoring platform and AI-enabled seizure detection capabilities.

Capital signal: Connected medical devices that shift monitoring into ambulatory and home settings can attract capital when clinical utility and reimbursement pathways become clearer.

Included Health signed a definitive agreement to acquire Firefly Health, combining virtual care and navigation with Firefly’s clinically integrated health plan and advanced primary-care model.

Transaction signal: The transaction highlights continued convergence across employer health benefits, care navigation, virtual primary care and risk-bearing health-plan models.

Flourish Health raised a $26 million Series A to scale its intensive in-home care model for children and young adults with serious and complex mental-health needs.

Capital signal: Early-stage capital is still available for differentiated behavioral-health care models when funding is tied to measurable access, acuity and care-delivery expansion.

CARPL.ai raised a $10 million Series A to expand its radiology-AI platform, product development and global commercial footprint.

Capital signal: Imaging AI capital is increasingly tied to interoperability, deployment infrastructure and multi-market distribution rather than a single algorithm.

Crystalys Therapeutics raised $130 million in Series B financing to support late-stage clinical trials and potential commercialization preparation for dotinurad.

Capital signal: Investors may fund later-stage clinical and commercial preparation when an asset has meaningful de-risking or regulatory precedent.

Focus agreed to acquire GuideIT, expanding its healthcare technology platform with additional managed services, digital transformation, and IT consulting capabilities.

Transaction signal: Healthcare IT consolidation is extending across services, infrastructure, applications, and workflow modernization. Buyers are building broader platforms that can serve health systems across more of the technology stack.

TYBR Health raised a $30 million Series A to expand commercial access to its FDA-cleared B3 GEL System and fund additional orthopedic clinical studies.

Capital signal: Commercial-stage device companies may raise equity to broaden indications and scale adoption after initial regulatory clearance.

Knox Lane completed its acquisition of Cross Country Healthcare, taking the healthcare workforce solutions company private. Cross Country serves healthcare clients across travel nursing, allied health, physician staffing, and workforce management.

Transaction signal: The transaction reflects sponsor interest in scaled healthcare workforce platforms even as labor markets normalize. Technology, client density, workforce data, and diversified staffing modalities can support a broader value-creation thesis.

Dentalcorp acquired Northstar Dental Partners, a Florida dental group supporting 21 practices, marking Dentalcorp’s first expansion into the United States.

Transaction signal: Cross-border DSO expansion shows how scaled dental platforms can use acquisitions to enter new geographies while retaining local clinical leadership and practice-level relationships.

Tempus AI agreed to acquire Personalis for approximately $1.5 billion. Personalis develops molecular residual disease testing for cancer, and the transaction is intended to deepen Tempus’ oncology diagnostics and monitoring capabilities.

Transaction signal: Precision diagnostics are increasingly converging with healthcare data and AI platforms. Buyers are seeking proprietary assays, longitudinal datasets, and clinical workflow integration that can extend across the cancer-care continuum.

PAX Health acquired MAKRAF IME, a New Jersey provider of psychology and neuropsychology independent medical examinations with a statewide examiner network.

Transaction signal: The transaction highlights consolidation in specialized behavioral-health assessment and medical-legal services, where clinical credentials, referral relationships and statewide coverage can create strategic value.

Bunkerhill Health raised a $25 million Series B led by Khosla Ventures, bringing total funding to $55 million, to expand its agentic-AI platform inside health systems.

Capital signal: Hospital AI funding is increasingly tied to enterprise deployment and workflow adoption rather than stand-alone technology narratives.

RapidPulse closed an oversubscribed $48 million Series B to fund its pivotal thrombectomy study and pursue FDA approval.

Capital signal: Neurovascular device financings can bridge pivotal clinical work, regulatory milestones and future commercialization.

Neko Health raised $700 million in Series C funding ahead of the launch of its preventive-health clinics in the United States.

Capital signal: Large late-stage rounds can function as expansion capital for healthcare delivery models that combine physical infrastructure, diagnostics and technology.

AdvanCell raised a $315 million Series D to advance its prostate-cancer radiopharmaceutical program toward phase 3 and expand manufacturing capacity.

Capital signal: Large late-stage rounds can finance both pivotal development and specialized manufacturing infrastructure ahead of commercialization.

Guardian Dentistry Partners entered a definitive agreement for a strategic majority acquisition of Select Dental Management, which supports 38 locations across eight states and Washington, D.C.

Transaction signal: Majority DSO transactions continue to emphasize multi-state density, doctor alignment, infrastructure leverage and the ability to support future add-on growth.

410 Medical completed a $12 million growth round to scale commercial operations and support the next generation of its LifeFlow rapid-infusion platform.

Capital signal: Growth capital can support commercial expansion of established devices without requiring a control transaction.

Draig Therapeutics raised a $65 million Series B to advance a neurological pipeline led by a phase 2-stage candidate for major depressive disorder.

Capital signal: Neuropsychiatric drug-development capital can provide another financing avenue within the broader behavioral-health ecosystem while remaining distinct from provider-services M&A.

Chai Discovery raised a $400 million Series C to expand its AI-driven drug-discovery models after signing partnerships with major pharmaceutical companies.

Capital signal: AI-enabled drug discovery is attracting large growth rounds where technology has demonstrated real-world adoption by strategic pharmaceutical partners.

Sage secured a $35 million specialized debt facility from Stifel Bank to support expansion of its senior-care technology and Hardware-as-a-Service model.

Capital signal: Debt facilities can complement equity rounds when a healthcare technology company has identifiable growth investments, contracted customers or capital-efficient deployment needs.

Family & Children’s Services of Tulsa and Hope Community Services of Oklahoma City completed their merger, combining two large behavioral-health organizations serving communities across Oklahoma.

Transaction signal: Nonprofit behavioral-health combinations can create statewide scale, broaden access and consolidate administrative and clinical infrastructure even when the transaction does not involve a disclosed purchase price.

Celea Therapeutics raised $180 million in debut financing to take its antifibrotic candidate into a phase 3 study.

Capital signal: Large formation financings can effectively capitalize a new company around a later-stage asset and provide a non-M&A path for portfolio repositioning.

UnitedHealth Group disclosed that Optum completed its acquisition of Alegeus, a technology platform supporting health benefit accounts and consumer-directed healthcare programs.

Transaction signal: The acquisition reflects continued convergence between benefit administration, payments, consumer engagement, and healthcare technology. Scaled platforms with embedded payer and employer workflows remain strategically relevant.

Peak Rock Capital agreed to acquire Asembia, a specialty pharmacy services, technology, and network platform. The founding family is expected to retain a minority interest.

Transaction signal: Specialty pharmacy infrastructure remains attractive where technology, manufacturer services, pharmacy networks, and patient-access workflows create recurring relationships across the drug-delivery ecosystem.

Assort Health raised a $120 million Series C led by Menlo Ventures at a reported $1.2 billion valuation to scale AI agents used across the patient journey.

Capital signal: Large healthcare AI rounds are increasingly concentrated in platforms with broad workflow penetration and demonstrable provider adoption.

xCures closed a $46 million Series B to expand its platform for converting fragmented medical records into decision-ready clinical data.

Capital signal: Clinical-data infrastructure can attract growth capital when it addresses interoperability and workflow problems with clear enterprise use cases.

Ollin Biosciences raised a $330 million Series B to advance its ophthalmology candidate through a multi-trial phase 3 program.

Capital signal: Mega-rounds can concentrate capital in companies with compelling clinical data and expensive late-stage development programs.

H.B. Fuller made a recommended cash offer to acquire Advanced Medical Solutions Group, a tissue-healing and surgical products company, at an implied enterprise value of £715 million.

Transaction signal: The transaction shows a diversified industrial buyer deliberately increasing exposure to healthcare through regulated, higher-margin medical technologies. Specialized regulatory know-how and direct clinical channels can broaden strategic buyer interest beyond traditional device companies.

Deaconess Associations Incorporated agreed to acquire 31 home health and hospice agencies from HCA Healthcare, including 24 home health agencies and seven hospice agencies across eight states.

Transaction signal: Large home-based-care divestitures can quickly reshape geographic scale and referral density. Buyers may value local clinical teams, payer relationships and care-continuum positioning even when the seller is pruning noncore assets.

Cadence raised a $100 million Series C led by Spark Capital to scale AI-enabled chronic-care delivery for older adults with chronic disease.

Capital signal: Growth capital is flowing toward care models that pair clinical operations with automation and recurring payer or provider relationships.

Serapha Bio launched with a $230 million financing package consisting of a Series A and additional funding tied to its reverse-merger formation and licensed therapeutic program.

Capital signal: Company formation, asset licensing and capital raising can be combined into a single strategic transaction that sits between traditional venture financing and M&A.

Prosper AI raised a $30 million Series A led by Andreessen Horowitz to scale an AI platform spanning patient scheduling, insurance verification and billing.

Capital signal: Administrative AI is drawing growth capital where products can influence both patient access and provider revenue-cycle performance.

Abarca Health and LucyRx announced a strategic combination that is expected to create an independent pharmacy benefit manager serving more than 9 million members across commercial and government markets.

Transaction signal: PBM consolidation reflects the strategic importance of scale, claims infrastructure, pharmacy networks and technology as independent operators compete with vertically integrated incumbents.

WPS Health Solutions acquired Mavida Health, a digital mental-health provider focused on women and families across fertility, pregnancy, postpartum and other reproductive-life stages.

Transaction signal: The deal shows payers and health-services organizations moving upstream into targeted virtual care and behavioral-health delivery, creating convergence between insurance, digital health and provider services.

Abry Partners closed a $780 million oversubscribed continuation vehicle for Centauri Health Solutions, with Neuberger Private Markets and Apollo S3 serving as co-lead investors.

Capital signal: Continuation vehicles can provide liquidity to existing investors while allowing a sponsor to retain a healthcare asset and fund another phase of growth. This is directly relevant to recapitalization, shareholder-liquidity and structured-capital advisory.

Danaher completed its $9.9 billion acquisition of Masimo, adding patient-monitoring and pulse-oximetry technologies to a diagnostics portfolio that includes Radiometer.

Transaction signal: The transaction shows how strategic buyers can pursue device businesses that deepen hospital call points and create cross-selling opportunities across larger diagnostics portfolios.

Ethyreal Bio exited stealth with $101 million raised across Series A and Series B financings to advance a thyroid-eye-disease program into human testing.

Capital signal: Back-to-back early financings can capitalize a new therapeutic company through successive development milestones without a control transaction.

GT Medical Technologies raised an oversubscribed $100 million Series E to expand commercialization of GammaTile and fund additional clinical development in brain tumors.

Capital signal: Late-stage medtech financing can provide substantial non-control capital for commercial scale and clinical evidence generation.

CereVasc completed the initial closing of an $85 million Series C to support pivotal development and regulatory work for its minimally invasive eShunt System.

Capital signal: Series C capital frequently funds pivotal studies and regulatory milestones before commercial launch.

Ascension completed its acquisition of AMSURG, adding more than 250 ambulatory surgery centers to its care-delivery network and materially expanding its outpatient footprint.

Transaction signal: The transaction reflects health-system interest in ambulatory capacity and site-of-care diversification. Large ASC networks can provide geographic density, physician alignment, and lower-cost procedural settings outside traditional hospitals.

National HealthCare Corporation acquired five skilled nursing facilities in a transaction valued at approximately $50.5 million, expanding its post-acute care footprint.

Transaction signal: Skilled nursing transactions continue to be shaped by local density, reimbursement exposure, occupancy, labor, and real-estate structure. Strategic operators can use targeted acquisitions to deepen existing regional networks.

Advanced NanoTherapies closed an oversubscribed Series B of more than $31 million for its dual-drug balloon platform for coronary and peripheral artery disease.

Capital signal: Strategic and venture capital can fund development-stage devices as they move through breakthrough-designation and clinical pathways.

NewLimit raised a $435 million Series C to advance longevity-focused medicines toward clinical testing and expand its platform.

Capital signal: Large platform rounds can finance long-duration R&D programs when investors underwrite both a lead asset and the broader discovery engine.

Curio acquired Nora Mental Health, a multi-state franchise system of community-based mental-health clinics, bringing the clinical footprint and franchise infrastructure onto Curio’s behavioral-health platform.

Transaction signal: Franchise and multi-site behavioral-health models can attract strategic buyers when they provide replicable operations, local market expansion and a scalable provider network.

Kids Clinic India, which operates Cloudnine, agreed to combine with Apollo Health and Lifestyle’s Apollo Cradle and Apollo Fertility businesses, creating a platform with more than 55 centers while AHLL retains a 9.9% stake.

Transaction signal: Women’s health and fertility platforms can create scale through combinations that preserve seller rollover equity while consolidating brands, clinicians and center networks.

Nourish raised a $100 million Series C led by Menlo Ventures to expand its virtual metabolic-care model, provider network and AI tools.

Capital signal: Capital is supporting virtual-care platforms that combine clinical delivery, payer relationships and technology rather than relying on software-only business models.

9amHealth raised a $26 million Series B led by Define Ventures to expand its AI-enabled virtual specialty-care platform beyond cardiometabolic conditions.

Capital signal: Series B capital can fund category expansion once a virtual-care platform has established a core clinical model and employer or payer distribution.

A U.S. bankruptcy court approved the sale of CVS Health’s Omnicare long-term-care pharmacy business to GenieRx Holdings for $250 million in cash plus certain assumed liabilities.

Transaction signal: The transaction illustrates distressed and special-situations M&A in pharmacy services, where legal liabilities, customer continuity, working capital and operating turnaround requirements can materially affect deal structure.

Isomorphic Labs raised a $2.1 billion Series B to fund development of next-generation AI drug-design models and its broader discovery platform.

Capital signal: The size of the round highlights investor willingness to capitalize AI-driven life-sciences platforms at a scale historically associated with public markets or large strategic transactions.

Sanford Health and North Memorial Health signed a definitive agreement to combine in May and finalized the partnership on September 1, 2026. The organizations now operate as one nonprofit integrated health system under Sanford Health.

Transaction signal: Health-system combinations in 2026 increasingly reflect proactive capability building rather than distress alone. Regional scale, specialty access, capital needs, and operating resilience remain central strategic considerations.

Amulet Capital Partners announced an investment in TFP Fertility Group, a European fertility-services platform. The transaction supports continued expansion of the group’s network and clinical capabilities.

Transaction signal: Fertility remains a specialized provider-services segment where scale, physician recruitment, laboratory quality, referral networks, and patient conversion can shape platform value and sponsor interest.

Enzo Health raised a $20 million Series A led by N47, bringing total funding to $26 million, to expand its AI-driven operating platform across home health, skilled nursing and hospice.

Capital signal: Home-based care technology can attract capital when it addresses referral, clinical documentation, compliance and reimbursement workflows across fragmented post-acute providers.

Carlyle acquired Knack RCM and EqualizeRCM and combined the businesses to create a scaled revenue-cycle management platform with technology-enabled and AI-oriented capabilities.

Transaction signal: Sponsor-backed healthcare technology platforms are increasingly being built around measurable workflow automation and labor productivity. RCM remains a particularly active area because technology can directly affect cash conversion and operating leverage.

LEO Pharma agreed to acquire Replay for $50 million upfront plus additional milestones and tiered royalties, adding Replay’s HSV-based gene-therapy platform for rare genetic skin disease.

Transaction signal: Smaller strategic biotech acquisitions can pair modest upfront consideration with contingent economics to transfer platform control while preserving upside for sellers if development succeeds.

Coultreon Biopharma raised a $125 million Series A after rebranding from Onco3R Therapeutics to advance autoimmune-disease assets acquired from Galapagos.

Capital signal: New-company financings can provide capital for teams to advance assets carved out or redirected from larger pharmaceutical portfolios.

beBright acquired Pediatric Dentistry of Shreveport-Bossier, adding six locations, 10 pediatric dentists and more than 100 staff members in Louisiana.

Transaction signal: Specialty dental platforms can use larger affiliations to add clinician density, regional scale and complementary pediatric or orthodontic capabilities while preserving local provider relationships.

Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, including an upfront payment and contingent clinical and regulatory milestones tied to Ajax’s hematology pipeline.

Transaction signal: Biopharma M&A continues to use milestone-based structures where a strategic buyer seeks control of a promising clinical asset but part of the consideration remains dependent on development outcomes.

Sun Pharmaceutical Industries signed a definitive agreement to acquire Organon for $14.00 per share in cash, valuing the women’s-health and biosimilars company at $11.75 billion in enterprise value.

Transaction signal: Large pharmaceutical acquisitions continue to be driven by portfolio diversification, global commercial scale, women’s-health franchises and the need to strengthen growth assets ahead of patent and pipeline transitions.

IKS Health agreed to acquire TruBridge, a healthcare technology and services company serving community and rural healthcare organizations, for $26.25 per share.

Transaction signal: The transaction extends consolidation across healthcare technology, revenue-cycle, and operational support services. Community and rural providers remain important customers for platforms that can spread technology and administrative capabilities across smaller organizations.

Cala Health secured $50 million in growth capital from Trinity Capital to support commercial expansion of its FDA-cleared wearable tremor therapy.

Capital signal: Growth capital can provide an alternative to a traditional equity round for commercial-stage healthcare businesses with established products and revenue.

ModMed acquired Bonsai Health, adding AI-powered patient engagement and workflow capabilities to its specialty healthcare technology platform.

Transaction signal: AI-enabled patient engagement is moving from standalone feature to platform capability. Acquirers are looking for technologies that can improve access, conversion, scheduling, and front-office productivity within existing clinical workflows.

Eli Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront plus milestone payments tied to Kelonia’s in vivo CAR-T technology.

Transaction signal: Milestone-heavy biotech acquisitions can bridge valuation gaps around early clinical assets while giving strategic buyers control of differentiated platforms with potentially large commercial upside.

Pulnovo Medical completed an oversubscribed $100 million strategic financing and entered a commercial agreement with lead investor Medtronic.

Capital signal: Strategic financings can combine capital with future commercialization pathways, creating alternatives to an outright sale.

Beeline Medicines launched with a $300 million Series A and a portfolio of autoimmune programs licensed from Bristol Myers Squibb.

Capital signal: Large formation rounds can pair experienced management, licensed assets and institutional capital to create a new standalone pharmaceutical platform.

Endovascular Engineering raised $80 million in Series C capital to support commercialization of its Hēlo thrombectomy platform for pulmonary embolism.

Capital signal: Commercialization-stage financings can provide substantial growth capital while preserving independence ahead of broader strategic alternatives.

ESO acquired d2i, adding analytics and emergency-care intelligence capabilities across fire, EMS, and health-system workflows.

Transaction signal: Emergency-care technology is consolidating around connected data, benchmarking, and operational intelligence. Platforms that bridge pre-hospital and hospital data can create differentiated workflow and analytics value.

Gilead Sciences entered a definitive agreement to acquire Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestone payments, adding a next-generation antibody-drug-conjugate platform.

Transaction signal: Strategic pharma buyers continue to use acquisitions to secure differentiated oncology technologies, with contingent consideration helping allocate development and commercialization risk.

Insight Health raised an $11 million Series A led by Standard Capital to scale voice-first clinical agents that automate referral, intake and scheduling workflows.

Capital signal: Workflow-specific AI companies are attracting early-stage capital when they can demonstrate labor savings inside clinical organizations.

Gyde acquired Avid Health, expanding its technology-enabled member engagement and benefits-navigation capabilities.

Transaction signal: Payer and benefits technology continues to converge around navigation, engagement, and consumer experience. Embedded relationships with plans and members can create strategic value even when broader managed-care M&A is selective.

IKS Health completed an acquihire of ThinkDTM, adding AI and technology talent to support its healthcare operations and digital transformation capabilities.

Transaction signal: Healthcare technology transactions are not limited to full platform acquisitions. Talent-led transactions can accelerate AI capability building where specialized engineering and healthcare-domain expertise are scarce.

eMed raised $200 million in Series A funding at a reported valuation above $2 billion to support its telehealth, GLP-1 management and population-health platform.

Capital signal: Large early institutional rounds can fund rapid scaling when a healthcare company has already built distribution, enterprise relationships and a differentiated operating model.

Endogenx raised $138 million in Series C financing for its non-thermal pulsed-electric-field platform targeting Type 2 diabetes.

Capital signal: Large clinical-stage device rounds show that investors will fund differentiated therapeutic technologies through capital-intensive development programs.

Gilgamesh Pharma raised a $60 million Series A for a portfolio of neuropsychiatric therapeutics after a prior licensing transaction led to a corporate spinout.

Capital signal: Capital raises can be part of a broader strategic restructuring in which assets are licensed, companies are separated and new equity is raised around the retained pipeline.

The Chartis Group acquired Leap AI, adding artificial-intelligence capabilities to its healthcare advisory and transformation platform.

Transaction signal: Healthcare services firms are increasingly buying AI capabilities rather than relying only on partnerships or internal development. Transactions that combine advisory relationships with proprietary technology can broaden both delivery capacity and recurring revenue potential.

Definity raised a $7 million Series A led by Accrete Health Partners to scale its vendor-neutral workforce-management platform for health systems.

Capital signal: Healthcare labor remains a strategic pain point, creating capital demand for technology that improves contingent-labor visibility, sourcing and workforce utilization.

Aveanna Healthcare agreed to acquire Family First Homecare, expanding its pediatric home-care and private-duty nursing footprint.

Transaction signal: Home-based care consolidation continues to center on clinical labor density, referral relationships, payor mix, geographic coverage, and the ability to recruit and retain specialized caregivers.

Universal Health Services agreed to acquire Talkspace in a transaction with an enterprise value of approximately $835 million, combining a scaled behavioral-health operator with a digital mental-health platform.

Transaction signal: The deal illustrates convergence between physical care networks and digital behavioral-health access. Strategic buyers can value technology platforms that extend reach, diversify channels, and create longitudinal patient relationships.

Sage raised a $65 million Series C led by Goldman Sachs Alternatives to expand its care platform and AI-enabled monitoring tools for senior living and skilled nursing.

Capital signal: Late-stage healthcare technology capital is increasingly tied to measurable deployment within care settings and to solutions that address labor and safety constraints.

Community Health Systems agreed to sell four Arkansas hospitals to Freeman Health System for approximately $112 million.

Transaction signal: Hospital portfolio rationalization remains an important source of transaction activity. Regional buyers can use divestitures to build scale while sellers redeploy capital toward core markets and balance-sheet priorities.

Surgery Partners acquired Preferred Vascular Group, an operator of eight ambulatory surgery centers focused on specialty dialysis-access procedures in Georgia and Ohio.

Transaction signal: ASC buyers continue to pursue specialty platforms where procedure migration, physician alignment and focused clinical capabilities can support durable growth and attractive site-of-care economics.

MUSC Health acquired Palmetto Primary Care Physicians, expanding its primary-care network and physician footprint in South Carolina. Public reporting placed the transaction at approximately $111 million.

Transaction signal: Health systems continue to invest in physician networks that can deepen referral capture, support population health, and expand ambulatory access. Primary-care density can be strategically important even when individual practice economics are modest.

Omni Family of Services acquired JusticeWorks YouthCare, expanding community-based behavioral and child-and-family services.

Transaction signal: Behavioral-health platforms continue to expand through adjacent community-based services where referral relationships, state programs, clinical workforce, and local operating density can support growth.

DoseSpot and Arrive Health merged to form Interra Health, combining e-prescribing and medication-access technology. Bain Capital Tech Opportunities became the majority owner of the combined business.

Transaction signal: Medication workflow platforms are combining prescribing, affordability, and access capabilities into broader infrastructure. Sponsor support can accelerate product integration and distribution across provider and pharmacy networks.

Altru Health System completed the transfer of CHI St. Alexius Health Devils Lake, adding the North Dakota hospital to its regional health-system network.

Transaction signal: Regional hospital transactions can be driven by local sustainability, access to capital, clinical integration, and the ability to preserve services in smaller markets.

Alignment Healthcare entered into a three-year $200 million senior secured revolving credit facility with Citibank and other lenders, providing liquidity that can be used for permitted acquisitions and other corporate purposes.

Capital signal: Revolving credit capacity gives healthcare companies acquisition dry powder and liquidity without requiring an immediate equity raise, making debt placement and capital-structure planning part of the broader transaction landscape.

Asahi Kasei agreed to acquire German antiviral drug developer AiCuris in a transaction reported at approximately €780 million.

Transaction signal: Pharma buyers continue to target specialized biotech pipelines that can add therapeutic depth and reduce reliance on internal R&D alone. Cross-border transactions remain an important part of pipeline replenishment.

GSK agreed to acquire 35Pharma for approximately $950 million in cash, adding clinical-stage assets to its development pipeline.

Transaction signal: Targeted biotech acquisitions remain an important mechanism for large pharmaceutical companies to add differentiated programs and expand future growth options.

Slate Medicines raised a $130 million Series A to advance next-generation migraine therapies, including a lead monoclonal antibody licensed from DartsBio Pharmaceuticals.

Capital signal: Large Series A financings can establish a new therapeutic platform around in-licensed assets and fund the first clinical milestones.

Kinderhook Industries agreed to acquire Enhabit in a take-private transaction valued at approximately $1.1 billion enterprise value. Enhabit operates home health and hospice locations across the United States.

Transaction signal: The transaction highlights continued sponsor interest in scaled home-based care despite reimbursement and labor complexity. Branch density, clinical outcomes, referral relationships, and operating discipline remain central to underwriting.

Hims & Hers Health agreed to acquire Eucalyptus in a transaction valued at up to approximately $1.15 billion, expanding its global consumer-health and digital-care platform.

Transaction signal: Consumer health platforms are using M&A to add geographic reach, clinical capabilities, and new care categories. The transaction shows how digital-health value can depend on brand, patient acquisition, care delivery, and recurring relationships—not software alone.

Center for Social Dynamics acquired New Mexico-based Behavior Change Institute, expanding autism diagnostics, ABA therapy and behavioral-health services in the Southwest.

Transaction signal: Autism-services platforms continue to use M&A to add clinical capacity, geography and specialized diagnostic capabilities. Provider quality, payer relationships and clinician recruitment remain central underwriting considerations.

Prime Healthcare Foundation became the sole corporate member and parent of Central Maine Healthcare, completing a nonprofit health-system combination.

Transaction signal: Hospital affiliations can use nonprofit structures and membership transfers rather than conventional acquisition consideration. Governance, capital commitments, community obligations, and service continuity are often as important as headline purchase price.

Talkiatry announced $210 million of Series D financing led by Perceptive Advisors, with participation from existing and new equity investors and a debt facility from Banc of California.

Capital signal: The financing shows how scaled behavioral-health platforms can combine late-stage equity and debt to fund growth, technology investment and potential public-market readiness.

KeyCare raised $27.4 million in new financing led by HealthX Ventures to scale its Epic-integrated virtual-care platform for health systems.

Capital signal: Strategic health-system investors and specialized healthcare funds can provide growth capital to platforms that deepen rather than fragment existing clinical workflows.

Waters completed its combination with Becton Dickinson’s Biosciences & Diagnostic Solutions businesses. Based on Waters’ closing share price before completion, BD said the separated business was valued at approximately $18.8 billion.

Transaction signal: The Reverse Morris Trust combination created a much larger life-sciences and diagnostics platform with exposure to recurring regulated testing workflows. Portfolio separation and scale-building remain important strategic themes in diagnostics.

Eli Lilly agreed to acquire Orna Therapeutics in a transaction valued at up to approximately $2.4 billion, adding circular RNA technology and development programs.

Transaction signal: Large pharmaceutical companies continue to use M&A to acquire novel therapeutic modalities and platform technologies. Transactions around differentiated science can carry meaningful contingent value tied to development progress.

Choice Health at Home announced acquisitions of Cy-Fair Health Care, Alliant Home Health, Palliative and Hospice Care, and Senior Nannies Private Care, expanding across the in-home care continuum.

Transaction signal: Multi-company home-care acquisitions show the value of building an integrated continuum across skilled home health, hospice, palliative care and private-duty services while increasing regional density.

Community Health Systems completed the sale of three Pennsylvania hospitals to Tenor Health Foundation for $33 million in cash plus a $15 million note.

Transaction signal: Hospital divestitures can involve structured consideration and nonprofit buyers focused on maintaining local operations. Transaction economics often reflect facility performance, capital needs, and community continuity considerations.

Sword Health acquired Kaia Health for approximately $285 million, combining two digital musculoskeletal care platforms and expanding Sword’s employer and health-plan reach.

Transaction signal: Digital health consolidation is increasingly about category leadership, distribution, and the economics of scaled patient engagement. Buyers are combining overlapping platforms to deepen clinical pathways and reduce fragmented customer procurement.

Premier Care Dental Management acquired Blank Dental Group, a three-location dental practice in Ohio, continuing its regional expansion strategy.

Transaction signal: Smaller add-on acquisitions remain an important part of DSO platform building because they can add local density, provider relationships and operating leverage without requiring a large platform transaction.

Boston Scientific agreed to acquire Penumbra in a transaction valued at approximately $14.5 billion, significantly expanding its neurovascular and thrombectomy portfolio.

Transaction signal: The transaction is one of the largest medtech deals of 2026 and illustrates strategic willingness to pay for scaled, high-growth clinical franchises with differentiated device portfolios and strong procedure exposure.

Inquis Medical closed a $75 million Series C to accelerate U.S. commercial expansion of its thrombectomy system and advance its product pipeline.

Capital signal: Series C financing can support the transition from regulatory achievement to nationwide commercial scale.

Spiro Medical closed a $67 million Series A to develop an implantable pulmonary neuromodulation system for asthma and fund U.S. clinical and regulatory work.

Capital signal: Large Series A rounds can finance capital-intensive device development when a novel therapeutic platform requires multi-year clinical and regulatory execution.

RWJBarnabas Health and Englewood Health announced a definitive agreement for Englewood Health to join the larger New Jersey health system while maintaining its local identity.

Transaction signal: Independent health systems are increasingly evaluating partnerships from a position of strategic planning rather than waiting for distress. Clinical capabilities, capital access, physician alignment, and regional scale can drive these combinations.